Castle Biosciences receives Mizuho Outperform rating with $60 target price
CSTL•Mizuho initiated coverage of Castle Biosciences with an Outperform rating and a $60 target price.
Related News
APi Group beats Q3 revenue estimates on inspection, service demand, raises 2026 outlook
APG•
Merck anticipates underlying operating expenses to increase mid- to high-single digits in 2027
MRK•
Belden Q3 revenue rises 38%, slightly beats estimates
BDC•
ADC Therapeutics' Zynlonta shows 58.1% response rate in Japanese lymphoma study
ADCT•
Microsoft: TD Cowen raises target price to $650 from $625
MSFT•